🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Duchenne Muscular Dystrophy (DMD)

Multiparametric Ultrafast Ultrasound Biomarkers for Duchenne and Becker Muscular Dystrophies NCT07378553n/a1 site📍 Nantes Nantes University Hospital Study to Evaluate the Safety and Effectiveness of ELEVIDYS in Participants With Duchenne Muscular Dystrophy Treated in a Post-Marketing Setting NCT07542314Phase 41 site📍 Houston Sarepta Therapeutics, Inc. · Tests: ELEVIDYS, Sirolimus, Glucocorticoids, Antibiotics Registry for Duchenne and Becker Muscular Dystrophy NCT07402122n/a30 sites📍 Graz📍 Innsbruck📍 Linz Dr. Andreas Ziegler A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE) NCT06138639Phase 1, Phase 215 sites📍 Little Rock📍 Los Angeles📍 Sacramento Solid Biosciences Inc. · Tests: SGT-003 A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort NCT04626674Phase 112 sites📍 Little Rock📍 La Jolla📍 Los Angeles Sarepta Therapeutics, Inc. · Tests: delandistrogene moxeparvovec Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders NCT06147414n/a1 site📍 Paris Assistance Publique - Hôpitaux de Paris · Tests: Blood sample Pharmacokinetics and Safety of Givinostat in DMD Patients Ages From at Least 2 Years to Less Then 6 Years Old NCT06769633Phase 29 sites📍 Brussels📍 Milan📍 Roma Italfarmaco · Tests: Givinostat Hydrochloride, Givinostat Hydrochloride - Cohort 2 Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy NCT05016908n/a2 sites📍 Boston📍 Boston Massachusetts General Hospital Respiratory Progression in Adults With Duchenne Muscular Dystrophy. NCT07879989n/a13 sites📍 Bologna📍 Bosisio Parini📍 Calambrone Istituto Giannina Gaslini Invasive Home Ventilation in Denmark NCT07467187n/a1 site📍 Copenhagen Copenhagen University Hospital, Rigshospitalet Safety and Efficacy of KER-065 in Participants With Duchenne Muscular Dystrophy NCT07704099Phase 22 sites📍 Auckland📍 Christchurch Keros Therapeutics, Inc. · Tests: KER-065 Biomarker Development for Muscular Dystrophies NCT05019625n/a5 sites📍 Boston📍 Boston📍 Boston Massachusetts General Hospital PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD) NCT07429240Phase 1, Phase 22 sites📍 Little Rock📍 St Louis Precision BioSciences, Inc. · Tests: PBGENE-DMD (IV) Follow-up of NIV At Home in Patients with Duchenne Muscular Dystrophy NCT06773988n/a1 site📍 Leuven Universitaire Ziekenhuizen KU Leuven · Tests: Monitoring of NIV at home Transcriptomic Analysis to Put an End to Misdiagnosis in Patients With Rare Muscle Diseases NCT06833489NA1 site📍 Marseille Assistance Publique Hopitaux De Marseille · Tests: ARN extraction from muscle biopsies Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy NCT07172971Phase 11 site📍 Nashville Vanderbilt University Medical Center · Tests: SGLT-2 inhibitor, SGLT2 inhibitor Vasodilator and Exercise Study for DMD (VASO-REx) NCT06290713Phase 21 site📍 Gainesville University of Florida · Tests: Tadalafil, Placebo, Exercise Training Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials NCT07674758n/a9 sites📍 Sacramento📍 Washington D.C.📍 Chicago Vanderbilt University Medical Center Evaluating VM100 Nutritional Supplement for Improving Quality of Life in Duchenne Muscular Dystrophy Patients NCT07766980Phase 21 site📍 Gainesville University of Florida · Tests: VM100 Nutritional Supplement Wearable Technology to Evaluate Hyperglycemia and HRV in DMD NCT06124196n/a1 site📍 Nashville Vanderbilt University Medical Center · Tests: wearable technology A Remote Study Using Technology to Assess Outcomes in DMD NCT07423026n/a1 site📍 Oxford University of Oxford Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT NCT06564974n/a33 sites📍 Phoenix📍 Little Rock📍 Loma Linda Catalyst Pharmaceuticals, Inc. · Tests: Vamorolone ML-Based Multi-Sensor Fall Risk Screening in DMD NCT07015632n/a1 site📍 Seoul Seoul National University Hospital · Tests: Performance of the Upper Limb, Brooke Scale, grip strength test Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study NCT05982119NA8 sites📍 Liège📍 Prague📍 Cairo Centre Hospitalier Universitaire de Liege · Tests: ActiMyo/Syde Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) NCT07608432Phase 31 site📍 Hillsborough Dyne Therapeutics · Tests: Zeleciment Rostudirsen (DYNE-251), Placebo Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy NCT06900049EARLY Phase 11 site📍 Shanghai Shanghai Jiao Tong University School of Medicine · Tests: LE051 The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy NCT07092540n/a4 sites📍 Rochester📍 Stony Brook📍 Cincinnati University of Rochester Research on the Relationship Between Scoliosis, Pain, Quality of Life, and Trunk Muscle Compensation Patterns Among Patients with Duchenne Muscular Dystrophy. NCT06755138n/a1 site📍 Seoul Seoul National University Hospital · Tests: Observational Assessment Urinary Titin Biomarker in DMD NCT07332013NA1 site📍 Philadelphia Children's Hospital of Philadelphia · Tests: Descending stair walk A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45 NCT07038824Phase 1, Phase 215 sites📍 Ghent📍 Leuven📍 Liège Entrada Therapeutics, Inc. · Tests: ENTR-601-45, ENTR-601-45 - matching placebo
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy